clinical trial · NCT07717411
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's DiseaseTrontinemabPlacebo
brief summary
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
started
Nov 30, 2026
primary completion
Sep 3, 2032
completion
Sep 3, 2032
last updated
Sep 10, 2026
official title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol